Sazgar M. Treatment of women with epilepsy. Continuum. 2019;2(2):408–30.

Google Scholar 

•• Tomson T, Battino D, Bromley R, et al. Executive summary: management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on women and pregnancy. Epilepsia. 2019;21:497–517. This task force summarizes current recommendations based on available data for managing epilepsy in pregnancy. This includes expert consensus when data is limited.

Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32(2):246–52. https://doi.org/10.1097/WCO.0000000000000659.

Article  CAS  PubMed  Google Scholar 

Hernández-Díaz S, Smith CR, Shen A, for the North American AED Pregnancy Registry, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–9.

Article  PubMed  Google Scholar 

Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85:1029–34. https://doi.org/10.1136/jnnp-2013-306318.

Article  CAS  PubMed  Google Scholar 

Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530–8.

Article  CAS  PubMed  Google Scholar 

Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11. https://doi.org/10.1002/14651858.CD010224.pub2.

• Hernandez-Diaz S, Huybrechts KF, Desai RJ, et al. Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology. 2018;90:342–51. https://doi.org/10.1212/WNL.0000000000004857. This study notes the elevated risk of cleft lip/cleft palette that is associated with topiramate, and is dose-dependent.

Hernandez-Diaz S, Mittendorf R, Smith C, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol. 2014;123(1):21–8. https://doi.org/10.1097/AOG.0000000000000018.

Article  CAS  PubMed  Google Scholar 

Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systemic review and meta-analysis. Neurology. 2016;86:1344–52.

Article  PubMed  Google Scholar 

Paolini SL, Pilato M, Rajasekaran V, Waters JFR, Bagic A, Urban A. Outcomes in three cases after brivaracetam treatment during pregnancy. Acta Neurol Scand. 2020;141:438–41.

Article  CAS  PubMed  Google Scholar 

Landmark CJ, Rektorli L, Burns ML, et al. Pharmacokinetic data on brivaracetam, lacosamide, and perampanel during pregnancy and lactation. Epileptic Disord. 2021;23(2):426–31.

Article  PubMed  Google Scholar 

Zonegran. European Medicines Agency; 2023. https://www.ema.europa.eu/documents/product-information/zonegran-epar-product-information_en.pdf.

• Meador KJ, Pennell PB, May RC, et al. Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology. 2020;94(14):E1502–11. Severe pregnancy outcomes including fetal loss and malformations are higher in pregnancy in patients with epilepsy compared to healthy controls.

Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia. 1996;37:1242–4.

Article  CAS  PubMed  Google Scholar 

• McCluskey G, Kinney MO, Russell A, et al. Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register. Seizure. 2021;91:311–5. Higher rates of MCMs in infants exposed to zonisamide were found in this observational study compared to what was previously reported, which highlights the need for further study about the teratogenicity of zonisamide.

Holmes L. Annual update for 2022. The North American Antiepileptic Drug Pregnancy Registry; 2022. https://www.aedpregnancyregistry.org/annual-update-for-2022.

Vazquez B, Tomson T, Dobrinsky C, et al. Perampanel and pregnancy. Epilepsia. 2021;62:698–708. https://doi.org/10.1111/epi.16821.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa R, Magalhaes LM, Graca J, et al. Eslicarbazepine acetate exposure in pregnant women with epilepsy. Seizure. 2018;58:72–4. https://doi.org/10.1016/j.seizure.2018.04.007.

Article  PubMed  Google Scholar 

Zutshi D, Millis SR, Basha MM, Daimee MA, Srinivas M. Lacosamide serum concentrations during pregnancy. Epilepsy Behav. 2021;123:108253. https://doi.org/10.1016/j.yebeh.2021.108253.

Article  PubMed  Google Scholar 

Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology. 2015;85:866–72. https://doi.org/10.1212/WNL.0000000000001772.

Article  CAS  PubMed  Google Scholar 

•• Vajda FJE, O’Brien TJ, Graham JE, Hitchcock AA, Lander CM, Eadie MJ. Antiepileptic drug polytherapy in pregnant women with epilepsy. Acta Neurol Scand. 2018;138:115–21. https://doi.org/10.1111/ane.12965. The Australian Pregnancy Registry found that topiramate and valproate are often associated with the increased risk of MCMs seen in polytherapy.

Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016;87:1943–53. https://doi.org/10.1212/WNL.0000000000003157.

Article  CAS  PubMed  Google Scholar 

• Knight R, Wittkowski A, Bromley RL. Neurodevelopmental outcomes in children exposed to newer anti-seizure medications: a systematic review. Epilepsia. 2021;62(8):1765–79. This systematic review summarizes the literature of cognitive outcomes with newer ASMs. Lamotrigine and levetiracetam have reassuring data about cognitive outcomes thus far.

Cohen MJ, Meador KJ, May R, et al. Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study. Epilepsy Behav. 2019;92:154–64.

Article  PubMed  Google Scholar 

• Unnikrishnan G, Jacob NS, Salim S et al. Enduring language deficits in children of women with epilepsy and the potential role of intrauterine exposure to antiepileptic drugs. Epilepsia. 2020;61(11):2442–51. Lower language scores were seen in children born to pregnant patients, particularly when exposed to valproate or phenobarbitone in utero.

• Meador KJ, Cohen M J, Loring DW, et al. Two-year-old cognitive outcomes in children of pregnant women with epilepsy in the maternal outcomes and neurodevelopmental effects of antiepileptic drugs study. JAMA Neurol. 2021;78(8):927–36. Cognitive outcomes at age 2 years were not different between children born to patients with epilepsy and healthy controls.

•• Bjørk M-H, Zoega H, Leinonen MK, et al. Association of prenatal exposure to anti-seizure medication with risk of autism and intellectual disability. JAMA Neurol. 2022;79(7):672–81. https://doi.org/10.1001/jamaneurol.2022.1269. This cohort study found that in-utero exposure to valproate and topiramate were associated with increased risk of neurodevelopmental disorders.

Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Meador KJ, Pennell PB, May RC, et al. Effects of periconceptional folate on cognition in children of women with epilepsy: NEAD study. Neurology. 2020;94(7):e729–40. Perinatal folic acid supplementation is associated with higher full scale IQ scores in children of patients with epilepsy, highlighting the protective effects of folate.

Husebye ESN, Gilhus NE, Riedel B, et al. Verbal abilities in children of mothers with epilepsy. Neurology. 2018;91(9):e811–21.

Article  PubMed  PubMed Central  Google Scholar 

Husebye ESS, Gilhus NE, Spigset O, et al. Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero – the Norwegian Mother and Child Cohort Study. Eur J Neurol. 2020;27(4):667–75.

Article  CAS  PubMed  Google Scholar 

Dwyer ER, Filion KB, MacFarlane AJ, Platt RW, Mehrabadi A. Who should consume high-dose folic acid supplements before and during early pregnancy for prevention of neural tube defects? BMJ. 2022;377:3067728.

Google Scholar 

Valera-Gran D, Garcia de la Hera M, Navartete-Munoz EM, Fernandez-Somoano A, et al. Folic acid supplements during pregnancy and child psychomotor development after the first year of life. JAMA Pediatr. 2014;168(11):e142611.

Article  PubMed  Google Scholar 

• Compan Gabucio LM, Garcia de la Hera M, Torres Collado L, Fernandez-Somoano A, et al. The use of lower or higher than recommended doses of folic acid supplements during pregnancy is associated with child attentional dysfunction at 4–5 years of age in the INMA Project. Nutrients. 2021;13:327–43. Low dose (<400 ug/day) and high dose (>1000 ug/day) were associated with attention problems in children at age 4-5 years old, particularly male children. 

•• Vegrim HM, Dreier JW, Alvestad S, et al. Cancer risk in children of mothers with epilepsy and high-dose folic acid use during pregnancy. JAMA Neurol. Published online September 26, 2022. https://doi.org/10.1001/jamaneurol.2022.2977. This review found increased risk of childhood cancers in children exposed to high dose folic acid (defined as >1 mg) compared to those on low dose folic acid born to patients with epilepsy. This raises concern that high dose folic acid may be detrimental.

Pennell PB and Hovinga CA. Chapter 13 Antiepileptic drug therapy in Pregnancy I: gestation-induced effects on AED pharmacokinetics. International Review of Neurobiology, Academic Press, Volume 83, 2008, 227–240.

•• Pennell PB, Karanam A, Meador K, et al. Anti-seizure medication concentrations during pregnancy: results from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study. JAMA Neurol. 2022;79:370–9. This prospective cohort study found that dose-normalized concentrations of ASMs including lamotrigine, levetiracetam, lacosamide, oxcarbazepine, and zonisamide all significantly decreased during pregnancy.

La Neve A, Boero G, Francavilla T, et al. Prospective, case–control study on the effect of pregnancy on seizure frequency in women with epilepsy. Neurol Sci. 2015;36(1):79–83.

Article  PubMed  Google Scholar 

Schmidt J, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol. 1983;46:751–5.

CAS  Google Scholar 

The EURAP Study Group. Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66(3):354–60.

Article  Google Scholar 

Battino D, Tomson T, Bonizzoni E, et al. Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry. Epilepsia. 2013;54(9):1621–7.

Article  CAS  PubMed  Google Scholar 

•• Pennell PB, French JA, May RC, et al. Changes in seizure frequency and antiepileptic therapy during pregnancy. New Engl J Med. 2020;383(26):2547–56. There was not a significant difference in seizure frequency between pregnant patients and non-pregnant controls over in this prospective observational cohort study. However, doses of seizure medications were changed more often in pregnant patients.

Baishya J, Jose M, Reshma AS, Sarma PS, Thomas SV. Do women with epilepsy benefit from epilepsy specific pre-conception care? Epilepsy Res. 2020;160:1–4.

Article  Google Scholar 

Ip S, Chung M, Raman G, Trikalinos TA, Lau J. A summary of the agency for healthcare research and quality’s evidence report on breastfeeding in developed countries. Breastfeed Med. 2009;4(SPECIAL ISSUE).

Al-Faraj AO, Pandey S, Herlihy MM, Pang TD. Factors affecting breastfeeding in women with epilepsy. Epilepsia. 2021;62(9):2171–9.

Article  CAS  PubMed  Google Scholar 

Shawahna R, Zaid L. Concentrations of anti-seizure medications in breast mild of lactating women: a systematic review with qualitative synthesis. Seizure. 2022;98:57–70.

Article  PubMed  Google Scholar 

•• Birnbaum AK, Meador KJ, Karanam A, et al. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurol. 2020;77(4):441–50. This prospective cohort study evaluates the concentration of ASM in infant serum compared to mother’s serum during breastfeeding. In general, ASM concentrations were much lower in infants compared to mothers, lending support to breastfeeding for lactating patients with epilepsy.

Vajda FJE, Graham JE, Hitchcock AA, Lander CM, O’Brien TJ, Eadie MJ. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure. 2019;65:6–11. https://doi.org/10.1016/j.seizure.2018.12.006. Elsevier online serial.

Article  CAS  PubMed  Google Scholar 

Thomas SV, Jeemon P, Pillai R, et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). Seizure. 2021;93:127–32. https://doi.org/10.1016/j.seizure.2021.10.015. Elsevier online serial.

Article  PubMed  Google Scholar 

Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692–9 Online serial.

Article  PubMed  Google Scholar 

Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193–8.

Article  CAS  PubMed  Google Scholar 

Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology. 2008;71:272–6.

Article  CAS  PubMed